Application of flow cytometry to platelet disorders

被引:98
作者
Linden, MD
Frelinger, AL
Barnard, MR
Przyklenk, K
Furman, MI
Michelson, AD
机构
[1] Univ Massachusetts, Sch Med, Ctr Platelet Funct Studies, Worcester, MA 01655 USA
[2] Univ Massachusetts, Sch Med, Dept Emergency Med, Worcester, MA 01655 USA
[3] Univ Massachusetts, Sch Med, Dept Anesthesiol, Worcester, MA 01655 USA
关键词
platelets; flow cytometry; platelet disorders; platelet activation; acute coronary syndromes;
D O I
10.1055/s-2004-835671
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Flow cytometry is a powerful and versatile tool that can be used to yield definitive information regarding the phenotypic status of platelets. The method provides a quantitative assessment of the physical and antigenic properties of platelets (e.g., surface expression of receptors, bound ligands, components of granules, or interactions of platelets with other platelets, other blood cells, or components of the plasma coagulation system), thereby facilitating the diagnosis of inherited or acquired platelet disorders (e.g., Bernard-Soulier syndrome, Glanzmann thrombasthenia, storage pool disease), the pathological activation of platelets (e.g., in the setting of acute coronary syndromes, cerebrovascular ischemia, peripheral vascular disease, cardiopulmonary bypass), and changes in the ability of platelets to activate via specific stimuli (e.g., efficacy of antiplatelet therapies). Accordingly, this review summarizes the key technical and methodologic components of flow cytometric analysis of platelets, as well as specific examples of its application to diagnosis and patient care.
引用
收藏
页码:501 / 511
页数:11
相关论文
共 156 条
[1]  
ABRAMS C, 1991, THROMB HAEMOSTASIS, V65, P467
[2]   COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J].
ALTMAN, R ;
CARRERAS, L ;
DIAZ, R ;
FIGUEROA, E ;
PAOLASSO, E ;
PARODI, JC ;
CADE, JF ;
DONNAN, G ;
EADIE, MJ ;
GAVAGHAN, TP ;
OSULLIVAN, EF ;
PARKIN, D ;
RENNY, JTG ;
SILAGY, C ;
VINAZZER, H ;
ZEKERT, F ;
ADRIAENSEN, H ;
BERTRANDHARDY, JM ;
BRAN, M ;
DAVID, JL ;
DRICOT, J ;
LAVENNEPARDONGE, E ;
LIMET, R ;
LOWENTHAL, A ;
MORIAU, M ;
SCHAPIRA, S ;
SMETS, P ;
SYMOENS, J ;
VERHAEGHE, R ;
VERSTRAETE, M ;
ATALLAH, A ;
BARNETT, H ;
BATISTA, R ;
BLAKELY, J ;
CAIRNS, JA ;
COTE, R ;
CROUCH, J ;
EVANS, G ;
FINDLAY, JM ;
GENT, M ;
LANGLOIS, Y ;
LECLERC, J ;
NORRIS, J ;
PINEO, GF ;
POWERS, PJ ;
ROBERTS, R ;
SCHWARTZ, L ;
SICURELLA, J ;
TAYLOR, W ;
THEROUX, P .
BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921) :81-100
[3]   Circulating platelet-derived microparticles with procoagulant activity may be a potential cause of thrombosis in uremic patients [J].
Ando, M ;
Iwata, A ;
Ozeki, Y ;
Tsuchiya, K ;
Akiba, T ;
Nihei, H .
KIDNEY INTERNATIONAL, 2002, 62 (05) :1757-1763
[4]  
[Anonymous], 1994, BMJ
[5]  
[Anonymous], LANCET
[6]   CORRELATED MEASUREMENT OF PLATELET-RELEASE AND AGGREGATION IN WHOLE-BLOOD [J].
AULT, KA ;
RINDER, HM ;
MITCHELL, JG ;
RINDER, CS ;
LAMBREW, CT ;
HILLMAN, RS .
CYTOMETRY, 1989, 10 (04) :448-455
[7]   Platelet activation in patients after an acute coronary syndrome: Results from the TIMI-12 trial [J].
Ault, KA ;
Cannon, CP ;
Mitchell, J ;
McCahan, J ;
Tracy, RP ;
Novotny, WF ;
Reimann, JD ;
Braunwald, E .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 33 (03) :634-639
[8]  
BARNARD MR, 2003, CURRENT PROTOCOLS CY
[9]   A platelet activation-specific monoclonal antibody that recognizes a receptor-induced binding site on canine fibrinogen [J].
Boudreaux, MK ;
Panangala, VS ;
Bourne, C .
VETERINARY PATHOLOGY, 1996, 33 (04) :419-427
[10]   Endothelial and platelet activation in acute ischemic stroke and its etiological subtypes [J].
Cherian, P ;
Hankey, GJ ;
Eikelboom, JW ;
Thom, J ;
Baker, RI ;
McQuillan, A ;
Staton, J ;
Yi, QL .
STROKE, 2003, 34 (09) :2132-2137